Monoclonal Anti-Brg1 antibody produced in rat

Monoclonal Anti-Brg1 (rat IgG1 isotype) is derived from the hybridoma 3G4 produced by the fusion of mouse myeloma cells (SP2) and lymph node cells from rat immunized with a synthetic peptide corresponding to a sequence at the C-terminal region of human Brm-related gene-1 (Brg1) protein. Brg1 or SWI/SNF (SWItch/Sucrose non-fermentable) related, matrix-associated, actin-dependent, regulator of chromatin, subfamily A, member 4 (SMARCA4) gene with 35 exons, is encoded by the gene mapped to human chromosome 19p13.

a synthetic peptide corresponding to a sequence at the C-terminal region of human Brg1 protein

Monoclonal Anti-Brg1 antibody produced in rat has been used in:

• immunoblotting (~185 kDa)
• flow cytometry
• immunofluorescence

Brm-related gene-1 (Brg1) (or hBrm) protein is the central catalytic ATPase of the SWI/SNF chromatin-remodeling complex, which is involved in transcriptional modulation of hormone-responsive promoters through binding of the complex to various nuclear receptors and its recruitment to gene-specific promoters. In addition, BRG1 has also been shown to act as a transcriptional repressor. It interacts with retinoblastoma tumor suppressor to form a repressor complex which inhibits cell cycle proteins such as cyclins A, D1 and E. BRG1 participates in the firing of origins and the process of replication elongation. This function of BRG1 also facilitates embryogenesis. In addition, It functions as a tumor suppressor and maintains genome stability and prevent cancer.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.